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Background: Chronic obstructive pulmonary disease (COPD) is characterised by progressive development of airflow
limitation that is poorly reversible. Because of a poor understanding of COPD pathogenesis, treatment is mostly
symptomatic and new therapeutic strategies are limited. There is a direct relationship between the severity of the
disease and the intensity of the inflammatory response. Besides smoking, one of the hypotheses for the persistent
airway inflammation is the presence of recurrent infections. Macrolide antibiotics have bacteriostatic as well as
anti-inflammatory properties in patients with cystic fibrosis and other inflammatory pulmonary diseases. There is
consistent evidence that macrolide therapy reduces infectious exacerbations, decreases the requirement for
additional antibiotics and improves nutritional measures. Because of these positive effects we hypothesised that
maintenance macrolide therapy may also have beneficial effects in patients with COPD who have recurrent
exacerbations. The effects on development of bacterial resistance to macrolides due to this long-term treatment are
unknown. Until now, studies investigating macrolide therapy in COPD are limited. The objective of this study is to
assess whether maintenance treatment with macrolide antibiotics in COPD patients with three or more
exacerbations in the previous year decreases the exacerbation rate in the year of treatment and to establish
microbial resistance due to the long-term treatment.
Methods/design: The study is set up as a prospective randomised double-blind placebo-controlled single-centre
trial. A total of 92 patients with COPD who have had at least three exacerbations of COPD in the previous year will
be included. Subjects will be randomised to receive either azithromycin 500 mg three times a week or placebo. Our
primary endpoint is the reduction in the number of exacerbations of COPD in the year of treatment.
Discussion: We investigate whether long-term therapy with macrolide antibiotics can prevent exacerbations in
patients with COPD. Additionally, our study aims to assess the effect of long-term use of macrolide on the
development of antimicrobial resistance and on inflammatory parameters related to COPD. We believe this study
will provide more data on the effects of macrolide treatment in patients in COPD and will add more knowledge on
its working mechanisms.
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Chronic obstructive pulmonary disease (COPD) is gener-
ally accepted to become one of the major health pro-
blems in the western worlds in the following years. The
main issue is the progressive character of the disease,
which is characterised by an ongoing development of
non-reversible airflow limitation.
COPD imposes a substantial burden on health-care
systems worldwide, as the disease is a major cause of
morbidity, mortality, reduced health status and a com-
mon cause of medical hospital admission [1]. Because of
a poor understanding of COPD pathogenesis, treatment
is mostly symptomatic and new therapeutic strategies are
limited. One of the known causes of COPD is long-term
exposure to noxious particles or gasses. Particularly
cigarette smoking is one of the main causes of develop-
ment of COPD [2]. All smokers show evidence of lung
inflammation, but smoking-induced lung injury is vari-
able and appears to be amplified only in a minority of
long-term tobacco smokers, suggesting that superim-
posed processes are the final determinants of COPD de-
velopment [3,4]. There is a direct relationship between
the severity of the disease and the intensity of the inflam-
matory response [3,4]. Thus, excessive inflammation is
likely the key to susceptibility. Inflammation persists long
after patients have stopped smoking. The cause of this
persistent airway inflammation is unknown although re-
current airway infections seem to play a role in this
process.
Macrolide antibiotics have bacteriostatic as well as
anti-inflammatory properties [5-7]. The anti-inflammatory
capacities of macrolides were firstly established in pulmon-
ary diseases as diffuse panbronchiolitis, a progressive in-
flammatory disorder of the airways found almost
exclusively in Japan [7]. The introduction of long-term
macrolide therapy has resulted in dramatic improvements
in survival, with 5-year survival rates increasing from 63 to
92% [7,8]. Significant symptom reduction and improved
pulmonary function have also been achieved [9-12]. The
mechanism of action is thought to be due to immune
modifying effects rather than direct antimicrobial ac-
tivity. Clinical improvement has been reported inde-
pendent of the presence or absence of chronic airway
infection [9] and with antibiotic levels below the mini-
mum inhibitory concentrations of several pathogenic
bacteria [13].
Also in patients with cystic fibrosis who are colonised
with Pseudomonas aeruginosa, macrolide therapy had
lead to improvement in forced expiratory volume in 1 s
(FEV1) and forced vital capacity (FVC), a reduction in
exacerbation rate, a reduction in hospital days and days
of intravenous antibiotic use, delaying time until the first
exacerbation and reducing number of additional courses
of antibiotics [14-19]. There is consistent evidence thatmacrolide therapy reduces infective exacerbations,
decreases the requirement for additional antibiotics and
improves nutritional measures in patients with cystic fi-
brosis. A Cochrane review of macrolide therapy con-
cluded that treatment with azithromycin had a small but
significant effect on pulmonary function in patients with
cystic fibrosis [20].
Although currently the use of maintenance antibiotic
treatment in COPD, other than for treating infectious
exacerbations COPD, is not recommended by the GOLD
report [21]. Several studies have been conducted to as-
sess the effect of long-term therapy with macrolide anti-
biotics in patients with COPD [22-24]. The results of
these studies are conflicting; however some suggest that
macrolide antibiotics may become a valuable therapeutic
option for COPD patients in preventing exacerbations.
There are essential differences between the different
macrolides . From previous studies on macrolide antibio-
tics it seems that azithromycin is the most potent drug
pharmacodynamically [25]. In contrast with erythro-
mycin and clarithromycin, it has a better intracellular
uptake, a slower release from cells and a more extensive
tissue distribution for a longer lasting effect after cessa-
tion of therapy [25,26]. Azithromycin also is known for
its mild side effects in comparison with erythromycin
[26-29]. Apart from that, in contrast to former studies
with macrolides in COPD [22-24] azithromycin can be
given on a three times weekly base.
In this randomised placebo controlled trial our main
aim is to assess whether maintenance treatment with
three times weekly azithromycin in COPD patients with
three or more exacerbations in the previous year can de-
crease the exacerbation rate in the year of treatment and
to study the effect of this treatment on microbial
resistance.
Methods
The study is designed as a prospective randomised
double-blind placebo-controlled single-centre trial in the
department of respiratory medicine in the Amphia
Hospital Breda, The Netherlands. Length of study is
determined at a period of 3 years, of which 2 years
will be spent on patient inclusion and 1 year on treat-
ment. The end of the study is defined by the last visit
of the last included subject.
Patient selection
All patients with COPD who have had three or more
exacerbations in the previous year will be asked to par-
ticipate in the study.
An exacerbation of COPD is defined by a (sub)acute
increase of pulmonary symptoms like dyspnoea, cough-
ing, increased sputum volume with or without puru-
lence, for which the patient has consulted a general
Table 1 Overview of outpatient department visits and
tests




Blood works X X X X X X
Microbiology X X X X X X
Lung function
testing
X X X X X
Rectal swab X X X
Questionnaires X X X X X X
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the patient has been admitted to the hospital. The health
care professional has judged the symptoms to be in such
a degree that treatment was given with systemic steroids
and/or a course of antibiotics.
The patients will be recruited from the outpatient de-
partment. To assess whether the patient fulfils the cri-
teria for study participation the study subjects’ GP will
be contacted to review the patient chart and medication
use. The hospital charts will be reviewed as well by the
investigator.
Inclusion criteria
– Diagnosis of COPD according to GOLD criteria
(FEV1/FVC< 70%), classification into GOLD I
(FEV1 80-100% predicted), GOLD II (FEV1 50-80%
predicted), GOLD III (FEV1 30-50% predicted) or
GOLD IV (FEV1 ≤ 30% predicted).
– Age ≥ 18 years.
– Three or more exacerbations of COPD in the
preceding year of inclusion for which a course of
systemic steroids and/or antibiotics therapy was
started.
– Clinically stable during 1 month. Patients have to be
free of COPD exacerbation or respiratory tract
infection within a month prior to involvement in the
study and in this period they should not have
received antibiotics or a course of high doses of




– Use of antibiotics or a course of high doses of
systemic steroids defined as more than 10 mg of
prednisone a day within a month prior to
involvement in the study.
– Addition of inhalation steroids to the patient’s
therapy regimen within 1 year prior to study
inclusion. Adding inhalation steroids 1 year before
trial inclusion can influence the outcome of
exacerbation frequencies.
– Pregnant or lactating women.
– Allergy to macrolides.
– Liver disease (alanine transaminase and/or aspartate
transaminase levels two or more times the upper
limit of normal).
– Asthma, defined as episodic symptoms of airflow
obstruction which is reversible with bronchodilators,
assessed with lung function testing.
– Bronchiectasis. A CT scan (1 mm coupes) was
performed in all patients to exclude bronchiectasis.Criteria of the BTS guideline Bronchiectasis (non-
CF) are used for radiologic definition of
bronchiectasis [30].
– Malignancy of any kind for which the subject is
under treatment or is being monitored as part of
follow up after treatment.
– Heart failure. A patient is excluded when having
clinical signs of heart failure and a cardiac function
defined as a left ventricular ejection fraction of less
than 45% confirmed by echocardiography or single
photon emission computed tomography (SPECT)
scan.
– Use of drugs that can adversely interact with
macrolides and for which therapeutic monitoring
cannot be undertaken, e.g. ergotamine derivatives.
Intervention
Subjects will be randomised to receive either azithromy-
cin 500 mg three times a week or placebo during a
1-year period. During this year subjects will be followed
at the outpatient department at 3, 6, 9 and 12 months
after initiating the study. During these visits the follow-
ing tests will be performed according to the flowchart
(Table 1):
– Lung function testing
– Sputum sample collection
– Peripheral blood collection
– Throat swab
– Rectal swab
– DS14 questionnaire for assessment of type D
personality (only on day 1 and month 12)
– Hospital Anxiety Depression Scale (HADS)
– 12-Item Short Form Health Survey (SF-12)
– St. George’s Respiratory Questionnaire (SGRQ).
In case of exacerbation subjects have the choice to get
treatment from their general practitioner or to visit the
hospital to be seen by the investigator. Either way spu-
tum and peripheral blood will be collected for immuno-
logical and microbiological investigations. Also the
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the SF-12, HADS and SGRQ.
Type D personality
The Type D Scale (DS14) will be administered to assess
Type D personality [31]. This 14-item questionnaire
comprises two subscales, Negative Affectivity and Social
Inhibition, each consisting of seven items. Items are
answered on a 5-point Likert scale, ranging from 0 (false)
to 4 (true). A standardised cutoff score ≥ 10 on both sub-
scales is used to classify individuals with a Type D per-
sonality [32]. A previous study confirmed that it is the
interaction of both traits, rather than the single traits,
that incurs an increased risk of adverse health outcomes
[32]. Both of the DS14 subscales of Negative Affectivity
and Social Inhibition have good internal validity (Cron-
bach’s α= 0.88/0.86), are stable over a 3-month period
(r= 0.82/0.72), and are independent of mood and health
status [31].
Depressive and anxious symptomatology
The Dutch version of the Hospital Anxiety and Depres-
sion Scale (HADS) will be used to assess depressive and
anxious symptomatology [33,34]. Both subscales consist
of seven items that are answered on a 4-point Likert
Scale, ranging from 0 to 3. A cutoff score of ≥ 8 for each
subscale represents probable clinical levels of anxiety
and depression [35]. Test-retest reliabilities over a
3-week period for the subscales and the total scale are
good (0.86< r< 0.91) [34]. The dimensional structure
and reliability of the HADS has been shown to be stable
across medical settings and age groups [24,34].
Health status
The Dutch version of the Short-Form Health Survey12
(SF-12) will be administered to assess generic health
status [36,37]. This generic instrument measures overall
physical and mental health status, as indicated by the
Physical Component Scale Summary (PCS) and the
Mental Component Summary (MCS) scores [38].
According to standard scoring procedures, all scale
scores will be standardised to the general US population
(range 0–100, mean = 50, SD= 10), with higher scores
indicating better functioning. The SF-12 has been
demonstrated to be a reliable and valid instrument [37].
Health-related quality of life
Disease specific health related quality of life will be mea-
sured by the total score on St. George’s Respiratory
Questionnaire (SGRQ) [39]. Three component scores are
calculated: symptoms, activity, and impacts (on daily
life), and a total score. Total scores range from 0 to 100,
with lower scores indicating improvement.Study endpoints
Primary study outcome
Reduction in the number of exacerbations of COPD in
the year of treatment.
Secondary study outcome
– Measurement of lung function parameters and 6 min
walking distance.
– Assessment of presence of type D personality by
DS14 questionnaire.
– Disease specific health related quality of life
measured by St. George’s Respiratory Questionnaire
(SGRQ).
– Generic health status measured by the 12-Item
Short Form Health Survey (SF-12).
– Indication of anxiety and depression by Hospital
Anxiety Depression Scale (HADS).
– Microbiology: Sputum specimens will be cultured.
Polymerase chain reaction (PCR) in sputum and
serology in serum for viral and atypical
microorganisms will be performed. The rectal swabs
will be tested for change in rectal flora as a result of
maintenance azithromycin.
– Measurement of inflammatory markers in serum
[erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), pro-adrenomedullin, (pro-ADM),
interleukin-6 and cytokine profiles of T-helper 1,
T-helper 2 and T-helper 17 cells].
– Decrease in percentage of clinical versus outpatient
department exacerbations.
– Difference in treatment effect between subjects with
and without steroid maintenance therapy as
hypothesis-generating secondary analysis.
– Adverse events of treatment. Symptoms that are
believed to be (possibly) related to therapy will be
reviewed at the outpatient department. If a patient
has an adverse event that is thought to be drug
related and that does not resolve, then the patient
will be withdrawn from the study. There will be no
routine ECG screening since azithromycin (in
contrast to erythromycin) is much less likely to be a
cause of a prolonged QTc interval.
– Length of hospital stay.
– Time till first exacerbation.
Sample size and statistical analysis
Power calculation and number of study subjects
This calculation starts with the assumption that the
number of exacerbations follows a pure Poisson distribu-
tion with a mean rate of 3 per subject per year in the
placebo group. A 50% reduction in this rate is considered
to be clinically relevant. Hence, in the active treatment
group the mean exacerbation rate is set at 1.5 per subject
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up for 1 year, this reduction is detectable with 90%
power, given a test size alpha of 0.05 (2-sided).
However, the assumption of a pure Poisson distribu-
tion may be too strong. In fact, it is plausible that in this
case a zero-inflated Poisson process may be present (the
outcome of zero exacerbations has a higher probability
than that following from a pure Poisson distribution). In
addition there is a risk of overdispersion (the variance is
larger than the mean). These phenomena may be
expected to have a negative (not exactly quantifiable
though) effect on the power of the study.
In order to reasonably compensate for the risk of a too
low power and for subjects dropping out within one year
follow-up, the number of subjects will be augmented by
40%, so that the sample size is set at 46 subjects per
treatment group.Statistical analysis
The exacerbation rate (primary efficacy outcome) will be
analysed using Poisson regression, with a log link func-
tion and the log of the time-under-treatment as offset.
The exacerbation rate ratio of active relatively to placebo
treatment will be the efficacy parameter of interest that
will be tested for significance at the 5% level (2-sided). In
addition a 95% confidence interval of this parameter will
be calculated. The following baseline covariates will be
entered along with treatment group: steroid maintenance
therapy, the number of exacerbations in the year preced-
ing randomisation, age, sex, smoking, and the GOLD cri-
teria (Tiffeneau index and FEV1% of predicted). In order
to generate hypotheses concerning the modification of
the treatment effect by the steroid therapy, the treat-
ment-by-steroid interaction term will be added to the
model and its effect will be explored. When necessary,
the scale parameter will be used to correct the SEs for
overdispersion. Additionally, a zero-inflated Poisson dis-
tribution will be fitted to the data in order to test if a
better fit is obtained.
Other continuous (secondary) outcome variables with
measurements at baseline, 3, 6, 9 and 12 months will be
analysed using mixed model ANOVA. The following
covariates will be entered in the model along with treat-
ment group: the baseline measurement of the outcome
variable, age, sex, smoking and the GOLD criteria. When
appropriate, the outcome variables will be suitably trans-
formed in order to obtain normally distributed residuals.
Time to first exacerbation will be analysed using Cox
proportional hazards regression with the following cov-
ariates entered in the model along with treatment group:
age, sex, smoking and the GOLD criteria. Also a Kaplan-
Meier curve for time to first exacerbation per treatment
group will be presented for illustrative purposes.Concerning safety, the number and type of adverse
event will be compared between the two treatment
groups using the chi square (or Fisher’s exact) test.
Randomisation
All eligible subjects will be randomised using block
randomisation sequences generated by computer.
Treatment allocation numbers will be entered into indi-
vidually sealed opaque envelopes. The envelope contains
a number that is concealed to the treatment allocation.
The allocation list will be kept in a safe in the hospital
pharmacy and access is possible by a non-investigator in-
dependently. In the event of an emergency medical situ-
ation the individual’s randomisation code and group
allocation could be identified.
Ethical aspects
The study has been approved by the ethics committee
Toetsingscommissie Wetenschappelijk Onderzoek Rot-
terdam (TWOR), the ethics committee of the Amphia
Hospital Breda and the Centrale Commissie Mensgebon-
den Onderzoek (CCMO).
The research will be explained in detail (verbally and
in writing) to the patient prior to enrolment in the study.
The explanation will include the type and method of the
research, the tests to be performed, and any potential
hazards. An informed consent in writing will be obtained
from each patient. The patient can withdraw from the
study at any time, without any repercussion for the on-
going care.
The study will be conducted according to the Inter-
national Conference for Harmonization (ICH) principles
of Good Clinical Practice (GCP) and the Declaration of
Tokyo (2004). The investigator will conduct all aspects
of this study in accordance with all national and regional
laws of the pertinent regulatory authorities.
Discussion
Despite the clinical efficacy of long-term macrolide treat-
ment in a number of respiratory diseases, until recently,
only smaller studies had reported on this subject in
patients with COPD. These studies showed conflicting
results. One study did examine the effect of clarithromy-
cin treatment in a prospective double-blind randomised
controlled trial including 67 patients with moderately se-
vere COPD [22]. The effects of 3 months’ clarithromycin
therapy on health status, exacerbation rate and sputum
bacterial numbers were measured. No significant benefit
was seen except for significant improvements in both the
St George’s Respiratory Questionnaire symptom score
and 36-item short-form health survey physical function
score. Another study investigated the influence of
erythromycin treatment on exacerbation of COPD [24].
The total number of patients needed for inclusion was
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However, the data suggested a beneficial effect in num-
ber of exacerbations. Recently Albert et al. [23] showed
in a large randomised controlled trial that adding daily
250 mg azithromycin to standard therapy reduced the
number of exacerbations in patients with COPD. The
major concern with this study, raised in a number of
comments and editorials, was the question about the de-
velopment of antimicrobial resistance, which had almost
doubled in that trial [40]. Also the question about the
working mechanism of azithromycin, whether it has an
antimicrobial or immunomodulatory effect, was not
answered in that trial.
With the current study we investigate whether long-
term therapy with macrolide antibiotics can prevent
exacerbations in patients with an instable COPD. Add-
itionally, our study aims to assess the effect of long-term
use of macrolides on the development of antimicrobial
resistance and on inflammatory parameters related to
COPD. We believe this study will provide more data on
the effects of macrolide treatment in patients in COPD
and will add more knowledge on its working mechanisms.
Trial status
The trial is currently recruiting study subjects.
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